Stanozolol 10mg*100 5mg*100 Tablets for Men Women Sex Improvement

Stanozolol 10mg*100 5mg*100 Tablets for Men Women Sex Improvement

Quick Detail:

Model NO.: 10418-03-8
Customized: non-customized
Suitable for: Adult
Purity: >99%
Character: White Tablets
MF: C21h32n2o
HS Code: 2937290090
Powder: No, Tablets
Certification: GMP, ISO 9001, SGS
State: Solid
Einecs: 233-894-8
MW: 328.49
Transport Package: Exquisite and Can According to Your Requirements
Origin: China
 

Detailed Description:

Stanozolol, sold under many brand names, is a synthetic anabolic–androgenic steroid (AAS) which was derived from dihydrotestosterone (DHT). It was developed by American pharmaceutical company Winthrop Laboratories (Sterling Drug) in 1962, and has been approved by the FDA for human use, though it is no longer marketed in this country.

Unlike most injectable AAS, stanozolol is not esterified and is sold as an aqueous suspension, or in oral tablet form. The drug has a high oral bioavailability, due to a C17α alkylation which allows the hormone to survive first-pass liver metabolism when ingested. It is because of this that stanozolol is also sold in tablet form.

Stanozolol is one of the AAS commonly used as performance-enhancing drugs and is banned from use in sports competition under the auspices of the International Association of Athletics Federations (IAAF) and many other sporting bodies. Additionally, stanozolol has been used in US horse racing.

Stanozolol has been used in both animals and human patients for a number of conditions. In humans, it has been demonstrated to be successful in treating anaemia and hereditary angioedema, the latter of which it has been specifically approved for the treatment of in some countries.[6] Veterinarians may prescribe the drug to improve muscle growth, red blood cell production, increase bone density and stimulate the appetite of debilitated or weakened animals.

History:
 

In 1962, Stanozolol was brought to market in the US by Winthrop under the tradename "Winstrol" and in Europe by Winthrop's partner, Bayer, under the name "Stromba".[12]

Also in 1962, the Kefauver Harris Amendment was passed, amending the Federal Food, Drug, and Cosmetic Act to require drug manufacturers to provide proof of the effectiveness of their drugs before approval.[13] The FDA implemented its Drug Efficacy Study Implementation (DESI) program to study and regulate drugs, including stanozolol, that had been introduced prior to the amendment. The DESI program was intended to classify all pre-1962 drugs that were already on the market as effective, ineffective, or needing further study.[14] The FDA enlisted the National Research Council of the National Academy of Sciences to evaluate publications on relevant drugs under the DESI program.

In June 1970 the FDA announced its conclusions on the effectiveness of certain AAS, including stanozolol, based on the NAS/NRC reports made under DESI. The drugs were classified as probably effective as adjunctive therapy in the treatment of senile and postmenopausal osteoporosis but only as an adjunct, and in pituitary dwarfism (with a specific caveat for dwarfism, "until growth hormone is more available"), and as lacking substantial evidence of effectiveness for several other indications. Specifically, the FDA found a lack of efficacy for stanozolol as "an adjunct to promote body tissue-building processes and to reverse tissue-depleting processes in such conditions as malignant diseases and chronic nonmalignant diseases; debility in elderly patients, and other emaciating diseases; gastrointestinal disorders resulting in alterations of normal metabolism; use during pre-operative and postoperative periods in undernourished patients and poor-risk surgical cases due to traumatism; use in infants, children, and adolescents who do not reach an adequate weight; supportive treatment to help restore or maintain a favorable metabolic balance, as in postsurgical, postinfectious, and convalescent patients; of value in pre- operative patients who have lost tissue from a disease process or who have associated symptoms, such as anorexia; retention and utilization of calcium; surgical applications; gastrointestinal disease, malnourished adults, and chronic illness; pediatric nutritional problems; prostatic carcinoma; and endocrine deficiencies."[16] The FDA gave Sterling six months to stop marketing stanozolol for the indications for which there was no evidence for efficacy, and one year to submit further data for the two indications for which it found probable efficacy.

In April 1984, the FDA announced that the data was not sufficient, and withdrew the marketing authority for stanozolol for senile and postmenopausal osteoporosis and for raising hemoglobin levels in aplastic anemia.

In 1988, Sterling was acquired by Eastman Kodak for $5.1 billion and in 1994 Kodak sold the drug business of Sterling to Sanofi for $1.675 billion.

Sanofi had stanzolol manufactured in the US by Searle, which stopped making the drug in October 2002.Even with no drug in production, Sanofi sold the stanozolol business to Ovation Pharmaceuticals in 2003, along with the two other drugs.[23] At that time, the drug had not been discontinued and was considered a treatment for hereditary angioedema. In March 2009, Lundbeck purchased Ovation

Stanozolol Benefit:

Stanozolol is often used by body builders in a cutting cycle to preserve the lean muscle mass.
This cycle also step up the utilization of fat tissues. Thereby bringing about the depletion of fats in the body.
It is interesting to note that the aim of the cutting cycle is not to increase the bulk of the muscle mass rather, to preserve the lean mass as the fat content of the body is cut down.
Stanozolol also have the ability to burn out these unwanted fat.
Stanozolol used in cutting cycles as oral tablets and injections have been found to increase the level testosterone in the body.
This aids the body to use up more testosterone to preserve lean muscle. This process also burns excess fat.

Other Related Products: